ReviewVaccines2020
Prospects and Challenges in the Development of Universal Influenza Vaccines.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Advances in the Development of a Universal Influenza Vaccine.Antibodies (Basel, Switzerland) · 2026Review
- Review
- Review
- Article
- Newcastle disease virus expressing clade 2.3.4.4b H5 hemagglutinin confers protection against lethal H5N1 highly pathogenic avian influenza in BALB/c mice.Frontiers in veterinary science · 2025Article
- Very Broadly Effective Hemagglutinin-Directed Influenza Vaccines with Anti-Herpetic Activity.Vaccines · 2024Article
- A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV.Frontiers in immunology · 2024Article
- Does Vaccine-Induced Maternally-Derived Immunity Protect Swine Offspring against Influenza a Viruses? A Systematic Review and Meta-Analysis of Challenge Trials from 1990 to May 2021.Animals : an open access journal from MDPI · 2023Review
- A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.Biomedicines · 2022Review
- Facile, Rapid, and Low-Cost Detection for Influenza Viruses and Respiratory Syncytial Virus Based on a Catalytic DNA Assembly Circuit.ACS omega · 2022Article
- Influenza NP core and HA or M2e shell double-layered protein nanoparticles induce broad protection against divergent influenza A viruses.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- Influenza Vaccine: An Engineering Vision from Virological Importance to Production.Biotechnology and bioprocess engineering : BBE · 2022Review
- Influenza Vaccines: Successes and Continuing Challenges.The Journal of infectious diseases · 2021Article
- Substantial effect of phytochemical constituents against the pandemic disease influenza-a review.Future journal of pharmaceutical sciences · 2021Review
- Efforts to Improve the Seasonal Influenza Vaccine.Vaccines · 2020Article
- Highly Immunogenic Nanoparticles Based on a Fusion Protein Comprising the M2e of Influenza A Virus and a Lipopeptide.Viruses · 2020Article
- High-Yield Expression and Purification of Recombinant Influenza Virus Proteins from Stably-Transfected Mammalian Cell Lines.Vaccines · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Current influenza vaccines offer suboptimal protection and depend on annual reformulation and yearly administration. Vaccine technology has rapidly advanced during the last decade, facilitating development of next-generation influenza vaccines that can target a broader range of influenza viruses. The development and licensure of a universal influenza vaccine could provide a game changing option for the control of influenza by protecting against all influenza A and B viruses. Here we review important findings and considerations regarding the development of universal influenza vaccines and what we can learn from this moving forward with a SARS-CoV-2 vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.